Pregnancy outcomes amongst multiple sclerosis females with third trimester Natalizumab use.
Conclusions: Complications following natalizumab administration during the second and third trimester of pregnancy occurred in 33% of newborns. However, did not result in mortality or morbidity. Dose alterations during the third trimester, pre-delivery umbilical cord sampling and IVIG administration may reduce hematological effects on newborns. Prospective studies with larger numbers of patients are required to provide further evidence regarding the safety of Natalizumab use in pregnancy.
AbstractThe novel coronavirus outbreak induces many concerns about the management of pregnancy, as well as rheumatic and musculoskeletal diseases. The very rapid spread of the infection throughout all inhabited continents leads to a fast-growing number of infected with SARS-CoV-2 and requires answers and special recommendations to the most vulnerable group of people: pregnant woman and patients on immunomodulatory or immunosuppressive treatment. A systematic literature search was performed in Embase, MEDLINE, and Scopus database for studies describing COVID-19 infection in pregnant women diagnosed with rheumatic and muscul...
We present two siblings, 13-year-old girl and 25-year-old boy with SPENCD, from consanguineous parents. Both patients had short stature, platyspondyly, metaphyseal changes, spastic paraparesis, mild intellectual disability, and juvenile-onset SLE. The age at disease-onset was 2 years for girl and 19 years for boy. Both had skin and mucosa involvement. The age at diagnosis of SLE was 4 years for girl, and 19 years for boy. The clinical diagnosis of SPENCD was confirmed by sequencing ofACP5 gene, which revealed a homozygous c.155A > C (p.K52T), a variant reported before as pathogenic. ...
AbstractRepurposing of antirheumatic drugs has garnered global attention. The aim of this article is to overview available evidence on the use of widely used antirheumatic drugs hydroxychloroquine, methotrexate and colchicine for additional indications. Hydroxychloroquine has endothelial stabilizing and anti-thrombotic effects. Its use has been explored as an adjunctive therapy in refractory thrombosis in antiphospholipid syndrome. It may also prevent recurrent pregnancy losses in the absence of antiphospholipid antibodies. Hydroxychloroquine favourably modulates atherogenic lipid and glycaemic profiles. Methotrexate has b...
Authors: Jastaneyah J, Reffler V, Engels L PMID: 32974706 [PubMed - in process]
Conclusion: In conclusion, patients with a ureteral catheter associated with APN should be given close attention with regards to the above risk factors. Early removal of the catheter is the best policy for the prevention of APN. PMID: 32975161 [PubMed - as supplied by publisher]
Publication date: Available online 25 September 2020Source: European Journal of Obstetrics &Gynecology and Reproductive BiologyAuthor(s): Michal Levy, Noa Gonen, Michal Kovo, Letizia Schreiber, Or Marom, Giulia Barda, Eldar Volpert, Jacob Bar, Eran Weiner
Publication date: November 2020Source: Multiple Sclerosis and Related Disorders, Volume 46Author(s): David Ellenberger, Peter Flachenecker, Judith Haas, Kerstin Hellwig, Friedemann Paul, Alexander Stahmann, Clemens Warnke, Uwe K. Zettl, Paulus S. Rommer, Scientific Advisory Group by the German MS-Register of the German MS Society
Conclusions: In the current analysis, the prevalence of postpartum depression was high as compared with other developing countries. Routine screening of mothers in the postpartum period and integrating mental health with maternal health care is highly recommended. PMID: 32974057 [PubMed]
ConclusionsComplications following natalizumab administration during the second and third trimester of pregnancy occurred in 33% of newborns. However, did not result in mortality or morbidity. Dose alterations during the third trimester, pre-delivery umbilical cord sampling and IVIG administration may reduce hematological effects on newborns. Prospective studies with larger numbers of patients are required to provide further evidence regarding the safety of Natalizumab use in pregnancy.
Objective:To assess hematological abnormalities (HA) and MS disease activity after exposure to natalizumab (NTZ) during pregnancy in women with highly active multiple sclerosis (MS).Background:Severe rebound after NTZ withdrawal might also occur during pregnancy, but anemia and thrombocytopenia will occure in 75% of newborns after NTZ exposure after the 30th gestational week. The best timepoint when to stop NTZ during pregnancy in women with aggressive MS is not known.Design/Methods:In this prospective, observational case series we compare relapses during pregnancy and HA in newborns of mothers exposed to NTZ less than 24 weeks (